Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTrellus Health. Regulatory News (TRLS)

  • This share is currently suspended. It was suspended at a price of 0.12

Share Price Information for Trellus Health. (TRLS)

Share Price is delayed by 15 minutes
Get Live Data
0.12    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £516.14k
TRLS Live PriceLast checked at - London Stock Exchange

Intraday Trellus Health. Share Chart

Holding(s) in Company

17 Apr 2024 16:16

RNS Number : 0238L
Trellus Health PLC
17 April 2024
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BNNFM402

Issuer Name

TRELLUS HEALTH PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Harwood Capital LLP

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

Name

City of registered office

Country of registered office

Harwood Capital Management (Gibraltar) Limited

Gibraltar

Gibraltar

Harwood Capital LLP

London

United Kingdom

4. Details of the shareholder

Name

City of registered office

Country of registered office

North Atlantic Smaller Companies Investment Trust Plc

London

United Kingdom

Oryx International Growth Fund Limited

Guernsey

Guernsey

Harwood Capital LLP

London

United Kingdom

5. Date on which the threshold was crossed or reached

16-Apr-2024

6. Date on which Issuer notified

17-Apr-2024

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

9.4916000

0.000000

9.4916000

15,329,667

Position of previous notification (if applicable)

10.760800

0.000000

10.760800

17,379,667

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BNNFM402

12,000,000

7.430000

GB00BNNFM402

0

 

0

 

GB00BNNFM402

 

3,329,667

 

 

2.061600

 

Sub Total 8.A

15,329,667

9.491600 %

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Christopher Harwood Bernard Mills

Harwood Capital LLP

9.491600

9.491600

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

17/04/24

13. Place Of Completion

London Stock Exchange

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEASLXFFDLEFA
Date   Source Headline
8th May 20267:30 amRNSSuspension - Trellus Health Plc
8th May 20267:00 amRNSUpdate on Funding & Suspension of Trading
28th Apr 20267:00 amRNSIssue of Equity - Conversion of Loan Notes
15th Apr 20267:00 amRNSIssue of Equity - Conversion of Loan Notes
13th Apr 20267:00 amRNSPfizer Licensing Agreement Renewal
8th Apr 20267:00 amRNSIssue of Equity - Conversion of Loan Notes
2nd Apr 20267:00 amRNSFunding Update
27th Mar 20267:00 amRNSMSA Signed and Funding Update
18th Mar 202612:29 pmRNSIssue of Equity - Conversion of Loan Notes
13th Mar 20268:45 amRNSHolding(s) in Company
13th Mar 20268:45 amRNSHolding(s) in Company
13th Mar 20268:43 amRNSHolding(s) in Company
13th Mar 20268:43 amRNSHolding(s) in Company
10th Mar 20267:01 amRNSHolding(s) in Company
10th Mar 20267:01 amRNSHolding(s) in Company
10th Mar 20267:00 amRNSIssue of Equity - Conversion of Loan Notes
2nd Mar 20267:00 amRNSIssue of Equity - Conversion of Loan Notes
26th Feb 20263:08 pmRNSHolding(s) in Company
23rd Feb 20267:00 amRNSIssue of Equity
18th Feb 20267:05 amRNSContract Extension with Johnson & Johnson
18th Feb 20267:00 amRNSIssue of Equity - Conversion of Loan Notes
11th Feb 20267:00 amRNSIssue of Equity
6th Feb 202610:45 amRNSHolding(s) in Company
3rd Feb 20265:37 pmRNSHolding(s) in Company
3rd Feb 20265:31 pmRNSHolding(s) in Company
3rd Feb 20267:00 amRNSBusiness update
29th Jan 20267:00 amRNSGrant of Share Options
22nd Jan 20267:00 amRNSHolding(s) in Company
20th Jan 20262:00 pmRNSResult of Meeting
19th Jan 20267:00 amRNSGrant of Share Options
30th Dec 20255:00 pmRNSProposed issue of Secured Convertible Loan Notes
30th Dec 20255:00 pmRNSProposed issue of Secured Convertible Loan Notes
24th Nov 20257:00 amRNSFinance update
7th Nov 20257:00 amRNSContract signed with second leading CRO
22nd Oct 20257:00 amRNSContract Signed with Leading Global CRO
21st Oct 20257:00 amRNSCompany Update
8th Sep 20253:15 pmRNSInterim results - Replacement
8th Sep 20257:00 amRNSInterim results
3rd Sep 20257:00 amRNSNotice of Results
12th Aug 20257:00 amRNSHolding(s) in Company
1st Jul 20257:00 amRNSResult of AGM
30th Jun 20257:00 amRNSAGM Statement
4th Jun 20257:00 amRNSPosting of Annual Report and Notice of AGM
2nd Jun 20257:00 amRNSFinal Results
23rd Apr 20254:30 pmRNSGrant of Share Options
4th Mar 20257:00 amRNSBusiness update
14th Jan 20257:00 amRNSAgreement with Johnson & Johnson
27th Dec 202410:30 amRNSChange of Registered Office
30th Sep 20247:00 amRNSHolding(s) in Company
26th Sep 20247:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.